Evidence map›Paper›PMID 38628442›Full record

ArticleFrontiers in molecular biosciences2023

Efficient deletion of microRNAs using CRISPR/Cas9 with dual guide RNAs.

Smitha Ijee, Karthik Chambayil, Anurag Dutta Chaudhury, Abhirup Bagchi, Kirti Modak, Saswati Das, Esther Sathya Bama Benjamin, Sonam Rani, Daniel Zechariah Paul, Aneesha Nath and 12 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 2 countries.

Smitha Ijee1 Centre for Stem Cell Research (A Unit of inStem, Bengaluru), Christian Medical College Campus, Vellore, India.
Karthik Chambayil *1 Centre for Stem Cell Research (A Unit of inStem, Bengaluru), Christian Medical College Campus, Vellore, India.
Anurag Dutta Chaudhury *Department of Haematology, Christian Medical College Campus, Vellore, India.
Abhirup Bagchi *1 Centre for Stem Cell Research (A Unit of inStem, Bengaluru), Christian Medical College Campus, Vellore, India.
Kirti Modak *Department of Haematology, Christian Medical College Campus, Vellore, India.
Saswati Das *Department of Biotechnology, Thiruvalluvar University, Vellore, India.
Esther Sathya Bama BenjaminSree Chitra Tirunal Institute of Science and Medical Technology, Thiruvananthapuram, India.
Sonam Rani1 Centre for Stem Cell Research (A Unit of inStem, Bengaluru), Christian Medical College Campus, Vellore, India.
Daniel Zechariah PaulDepartment of Haematology, Christian Medical College Campus, Vellore, India.
Aneesha Nath1 Centre for Stem Cell Research (A Unit of inStem, Bengaluru), Christian Medical College Campus, Vellore, India.
Debanjan RoyDepartment of Haematology, Christian Medical College Campus, Vellore, India.
Dhavapriya Palani1 Centre for Stem Cell Research (A Unit of inStem, Bengaluru), Christian Medical College Campus, Vellore, India.
Sweety PriyankaDepartment of Haematology, Christian Medical College Campus, Vellore, India.
Rakshini RavichandranDepartment of Haematology, Christian Medical College Campus, Vellore, India.
Betty K KumaryDepartment of Haematology, Christian Medical College Campus, Vellore, India.
Yazhini SivamaniDepartment of Haematology, Christian Medical College Campus, Vellore, India.
Vijayanand SDepartment of Biotechnology, Thiruvalluvar University, Vellore, India.
Dinesh Babu1 Centre for Stem Cell Research (A Unit of inStem, Bengaluru), Christian Medical College Campus, Vellore, India.
Yukio NakamuraCell Engineering Division, RIKEN BioResource Research Center, Tsukuba, Japan.
Vasanth Thamodaran1 Centre for Stem Cell Research (A Unit of inStem, Bengaluru), Christian Medical College Campus, Vellore, India.
Poonkuzhali BalasubramanianDepartment of Haematology, Christian Medical College Campus, Vellore, India.
Shaji R Velayudhan1 Centre for Stem Cell Research (A Unit of inStem, Bengaluru), Christian Medical College Campus, Vellore, India.
Christian Medical College & Hospital · INThiruvalluvar University · INSree Chitra Thirunal Institute for Medical Sciences and Technology · INRegional Centre for Biotechnology · INRIKEN BioResource Research Center · JPTata Institute for Genetics and Society · IN

Funding

Wellcome Trust
6 · The paper itself

Abstract

MicroRNAs (miRNAs) are short non-coding RNAs that play crucial roles in gene regulation, exerting post-transcriptional silencing, thereby influencing cellular function, development, and disease. Traditional loss-of-function methods for studying miRNA functions, such as miRNA inhibitors and sponges, present limitations in terms of specificity, transient effects, and off-target effects. Similarly, CRISPR/Cas9-based editing of miRNAs using single guide RNAs (sgRNAs) also has limitations in terms of design space for generating effective gRNAs. In this study, we introduce a novel approach that utilizes CRISPR/Cas9 with dual guide RNAs (dgRNAs) for the rapid and efficient generation of short deletions within miRNA genomic regions. Through the expression of dgRNAs through single-copy lentiviral integration, this approach achieves over a 90% downregulation of targeted miRNAs within a week. We conducted a comprehensive analysis of various parameters influencing efficient deletion formation. In addition, we employed doxycycline (Dox)-inducible expression of Cas9 from the AAVS1 locus, enabling homogeneous, temporal, and stage-specific editing during cellular differentiation. Compared to miRNA inhibitory methods, the dgRNA-based approach offers higher specificity, allowing for the deletion of individual miRNAs with similar seed sequences, without affecting other miRNAs. Due to the increased design space, the dgRNA-based approach provides greater flexibility in gRNA design compared to the sgRNA-based approach. We successfully applied this approach in two human cell lines, demonstrating its applicability for studying the mechanisms of human erythropoiesis and pluripotent stem cell (iPSC) biology and differentiation. Efficient deletion of miR-451 and miR-144 resulted in blockage of erythroid differentiation, and the deletion of miR-23a and miR-27a significantly affected iPSC survival. We have validated the highly efficient deletion of genomic regions by editing protein-coding genes, resulting in a significant impact on protein expression. This protocol has the potential to be extended to delete multiple miRNAs within miRNA clusters, allowing for future investigations into the cooperative effects of the cluster members on cellular functions. The protocol utilizing dgRNAs for miRNA deletion can be employed to generate efficient pooled libraries for high-throughput comprehensive analysis of miRNAs involved in different biological processes.

Indexed as

CRISPR-Cas9dual-gRNAerythroidiPSCsmiRNA

Identifiers

PMID38628442
PMCPMC11020096
OpenAlexW4393432192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.